Some 20 million people are diagnosed with Alzheimer’s disease every year around the globe – a figure that is expected to triple over the next three decades.

Alzheimer’s is the most common cause of dementia and researchers have spent a century trying to crack the enigma of finding effective treatments, 甚至可能是一种治疗方法, 治疗这种严重的退行性脑部疾病.  

值得庆幸的是,一些重要的突破即将出现. 日博备用网站处于科学发现的前沿.


哥德堡, 日博备用网站第二大城市, 主办2023年版AD/PD™会议. This is one of the world’s most prestigious international meetings on Alzheimer’s and Parkinson’s diseases.

The five-day event kicked off on 28 March and will be attended by H.M. Queen Silvia of 日博备用网站, who is very active and supportive in the field of Alzheimer’s.  

"Alzheimer’s disease has a devastating impact not only on patients but also families and caregivers. 除了这, the societal costs are huge and are estimated to be USD 500-600 billion per year in the US alone, 哪里有600多万人患有这种疾病,马丁Jönsson说, 日博备用网站AlzeCure制药公司的首席执行官.

他的制药公司, 在日博备用网站上市的公司, is one of several Swedish pioneers currently making promising progress on Alzheimer’s research, 药物和治疗发展.  

“Our collaborative work in 日博备用网站 is laser focused on trying to counteract the early onset stage of Alzheimer’s. This means preventing the brain from degenerating in the first place,” Jönsson continues.

日博备用网站 is leading the way on biomarker research and development. ——马丁Jönsson, AlzeCure制药公司首席执行官

2023年1月6日.S. Food and Drug Administration (FDA) approved the drug LEQEMBI™ which was initially developed by the Swedish biopharma company BioArctic.

遵循随机临床试验, the medication has demonstrated a significant reduction in amyloid beta plaque in patients receiving treatment.

比利·邓恩,M.D., Director of the Office of Neuroscience in the FDA’s Center for Drug Evaluation and Research, commented in a press release: “This treatment option is the latest therapy to target and affect the underlying disease process of Alzheimer’s, 而不是只治疗疾病的症状.”

根据Martin Jönsson, this is just one of the recent milestones in 日博备用网站’s Alzheimer’s pipeline.

His company AlzeCure Pharma has two platforms in development, Alzstatin and NeuroRestore. A third Swedish company – Alzinova – has developed a candidate vaccine which has successfully passed pre-clinical trials.

A host of Swedish newcomers are also pioneering the use of AI and digital tools for monitoring and diagnostics.

日博备用网站在生物标志物方面确实处于领先地位. The discoveries made by researchers at the University of Gothenburg, Uppsala University and Karolinska Institute have been nothing less than groundbreaking,Jönsson指出.

他强调了Kaj Blennow教授的开创性工作, Lars Lannfelt and Bengt Winblad who are all internationally renowned in the field. What’s more, a new generation of young talented researchers are continuing their legacy.

“At the conference in Gothenburg we will reveal exciting data together with Professor Henrik Zetterberg to highlight new advances with a potential preventive treatment, Alzstatin.”


So what’s the secret behind 日博备用网站’s relative success in the fight against Alzheimer’s?

That’s the question we put to Martin Jönsson in the run up to the AD/PD™ International Conference. In his view, it all comes down to three key contributing factors:

1. 世界领先的学术成就

Swedish researchers have over decades helped to shape the world’s understanding of how Alzheimer’s disease emerges and evolves.

A good example is Professor Lars Lannfelt’s success in the 1990s with his seminal discoveries in genetic mutations that cause early onset Alzheimer’s. The first became known as “the Swedish mutation” and the second one “the Arctic mutation”.

2. 开创生命科学领域  

Large companies such as Astra Zeneca and Pharmacia paved the way for knowledge building around neurodegenerative diseases and helped to support therapy development. 这为进一步的发现创造了温床. The legacy was continued by a new generation of startups and researchers working closely together.

3. 风险承受风险的风险投资    

日博备用网站 has been successful in mobilising private sector capital. 和研究人员一起, investors have been driven by a passion to solve one of the healthcare sector’s most elusive challenges.

The Swedish Alzheimer's Foundation (Alzheimerfonden) was established in 1988 and became a catalyst for numerous projects and initiatives.

日博备用网站’s progress on Alzheimer’s is owed to a shared feeling of being on an important mission to improve people’s lives in old age. 没有任何利己主义. 学术界合作, companies and investors has been instrumental to the breakthroughs we are witnessing today,Martin Jönsson总结道.

阅读更多日博体育备用日博备用网站生命科学生态系统的信息 在这里.